Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T18:02:24.748Z Has data issue: false hasContentIssue false
  • English
  • Français

Pulmonary hypertension in infancy and childhood

Published online by Cambridge University Press:  24 May 2005

Matthias Gorenflo ,
Mathias Nelle ,
Ph. A. Schnabel  and
Michael V. Ullmann
Matthias Gorenflo
Affiliation:
Department of Paediatric Cardiology, University Medical Centre, Heidelberg, Germany
Mathias Nelle
Affiliation:
Department of Neonatology, University Medical Centre, Heidelberg, Germany
Ph. A. Schnabel
Affiliation:
Department of Pathology, University Medical Centre, Heidelberg, Germany
Michael V. Ullmann
Affiliation:
Department of Cardiac Surgery, University Medical Centre, Heidelberg, Germany
Get access Rights & Permissions [Opens in a new window]

Abstract

In this review, we discuss current concepts in the pathogenesis and management of pulmonary hypertension affecting infants and children, with special focus on left-to-right shunting, bronchopulmonary dysplasia, and primary pulmonary hypertension.

In patients of these ages, functional aspects, such as an imbalance between vasoconstricting and vasodilating mechanisms, and morphological alterations of the vessel wall, contribute to the pulmonary hypertension. In the past decades, strategies have emerged for treatment that are targeted at the pathophysiological basis. Thus, in patients with left-to-right shunting and pulmonary hypertension after intra-cardiac repair, treatment with nitric oxide has been introduced effectively, while treatment with prostanoids, such as iloprost, is under investigation. In patients with pulmonary hypertension and bronchopulmonary dysplasia, therapeutic strategies focus on the underlying chronic lung disease and use of vasodilators. The pathogenesis of primary pulmonary hypertension in children remains as yet unclear, although treatment with prostanoids has proven effectively to improve the long-term prognosis.

Keywords

Aetiologyprimary pulmonary hypertensionbronchopulmonary dysplasiatreatment
Type
Review
Information
Cardiology in the Young , Volume 13 , Issue 3 , June 2003 , pp. 219 - 227
Copyright
© 2003 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–223.Google Scholar
Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197–1208.Google Scholar
Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension. World Health Organization, Geneva, 1998.
Haworth SG, Hislop AA. Pulmonary vascular development: normal values of peripheral vascular structure. Am J Cardiol 1983; 52: 578–583.Google Scholar
Ghanayem NS, Gordon JB. Modulation of pulmonary vasomotor tone in the fetus and neonate. Respir Res 2001; 2: 139–144.Google Scholar
Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 1995; 47: 87–131.Google Scholar
Crowley MR. Oxygen-induced pulmonary vasodilation is mediated by adenosine triphosphate in newborn lambs. J Cardiovasc Pharmacol 1997; 30: 102–109.Google Scholar
Sylvester JT. Hypoxic pulmonary vasoconstriction. A radical view. Circ Res 2001; 88: 1228–1230.Google Scholar
Hardin C. Making sense of oxygen sensing. J Physiol 2001; 536: 2.Google Scholar
Semenza GL. Oxygen-regulated transcription factors and their role in pulmonary disease. Respir Res 2000; 1: 159–163.Google Scholar
Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732–1739.Google Scholar
Wiedemann R, Ghofrani A, Weissmann N, et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. J Am Coll Cardiol 2001; 38: 1130–1136.Google Scholar
Beghetti M, Adatia I. Inhaled nitric oxide and congenital cardiac disease. Cardiol Young 2001; 11: 142–152.Google Scholar
Müller B. Pharmacology of thromboxane A2, prostacyclin and other eicosanoids in the cardiovascular system. Therapie 1991; 46: 217–221.Google Scholar
Jones RL, Qian Y, Wong HNC, Chan H, Yim APC. Prostanoid action on the human pulmonary vascular system. Clin Exp Pharmacol Physiol 1997; 24: 969–972.Google Scholar
Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533–547.Google Scholar
Haworth SG. Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood. Br Heart J 1984; 52: 557–571.Google Scholar
Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978; 58: 1107–1122.Google Scholar
Wagenvoort CA. Classification of pulmonary vascular lesions in congenital and acquired heart disease. Adv Cardiol 1974; 11: 48–55.Google Scholar
Wagenvoort CA, Wagenvoort N. Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol 1974; 11: 123–130.Google Scholar
Wagenvoort CA, Mooi WJ, Corrin B. Biopsy pathology of the pulmonary vasculature. (Biopsy pathology series No. 13.) Chapman and Hall Medical, London, 1989, pp 56–113.
Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiol Res 2000; 49: 485–492.Google Scholar
Allen K, Haworth SG. Cytoskeletal features of immature vascular smooth muscle cells: the influence of pulmonary hypertension on normal development. J Pathol 1989; 158: 311–317.Google Scholar
Wagenvoort CA, Wagenvoort N, Draulans-Noë Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg 1984; 87: 876–886.Google Scholar
Ivy D. Diagnosis and treatment of severe pediatric pulmonary hypertension. Cardiol Rev 2001; 9: 227–237.Google Scholar
Garofano RP, Barst RJ. Exercise testing in children with primary pulmonary hypertension. Pediatr Cardiol 1999; 20: 61–64.Google Scholar
Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13: 72–75.Google Scholar
Wilkinson JL. Haemodynamic calculations in the catheter laboratory. Heart 2001; 85: 113–120.Google Scholar
Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart 1997; 77: 299–301.Google Scholar
Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33: 813–819.Google Scholar
Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A–62A.Google Scholar
Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447–453.Google Scholar
Turanlahti MI, Laitinen PO, Sarna SJ, Pesonen E. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. Heart 1998; 79: 169–174.Google Scholar
Ichida F, Uese K-I, Tsubata S-I, et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997; 80: 662–664.Google Scholar
Gorenflo M, Bettendorf M, Brockmeier K, Ulmer HE. Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. Z Kardiol 2000; 89: 1000–1008.Google Scholar
Haworth SG. Primary pulmonary hypertension in childhood. Arch Dis Child 1998; 79: 452–455.Google Scholar
Egreteau L, Pauchard JY, Semama DS, Matis J, Liska A, Romeo B, Cneude F, Hamon I, Truffert P. Chronic oxygen dependency in infants born at less than 32 weeks' gestation: incidence and risk factors. Pediatrics 2001; 108: E26.Google Scholar
Gorenflo M, Vogel M, Herbst L, Bassir C, Kattner E, Obladen M. Influence of clinical and ventilatory parameters on morphology of bronchopulmonary dysplasia. Pediatr Pulmonol 1995; 19: 214–220.Google Scholar
Gorenflo M, Vogel M, Obladen M. Pulmonary vascular changes in bronchopulmonary dysplasia: a clinicopathologic correlation in short- and long-term survivors. Pediatr Pathol 1991; 11: 851–866.Google Scholar
Brownlee JR, Beekman RH, Rosenthal A. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res 1988; 24: 186–190.Google Scholar
Cockrill BA, Kacmarek RM, Fifer MA, et al. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001; 119: 128–136.Google Scholar
Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999; 103: 610–618.Google Scholar
Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 1996; 112: 1600–1607.Google Scholar
Bando K, Vijayaraghavan P, Turrentine MW, et al. Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation 1997; 96 (Suppl II): II346–II351.Google Scholar
Komai H, Adatia IT, Elliott MJ, de Leval MR, Haworth SG. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 1993; 106: 473–478.Google Scholar
Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000; 356: 1464–1469.Google Scholar
Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62: 1759–1764.Google Scholar
Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346: 51–52.Google Scholar
Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996; 153: 1985–1987.Google Scholar
Cueto E, Lopez-Herce J, Sanchez A, Carrillo A. Life-threatening effects of discontinuing nitric oxide in children. Acta Paediatr 1997; 86: 1337–1339.Google Scholar
Goldman AP, Haworth SG, Macrae DJ. Does inhaled nitric oxide suppress endogenous nitric oxide production? J Thorac Cardiovasc Surg 1996; 112: 541–542.Google Scholar
Pearl JM, Nelson DP, Raake JL, et al. Inhaled nitric oxide increases endothelin-1 levels: A potential cause of rebound pulmonary hypertension. Crit Care Med 2002; 30: 89–93.Google Scholar
Turanlahti MI, Laitinen PO, Pesonen EJ. Preoperative and postoperative response to inhaled nitric oxide. Scand Cardiovasc J 2000; 34: 46–52.Google Scholar
Lutz J, Gorenflo M, Habichhorst M, Vogel M, Lange PE, Hocher B. Endothelin-1 and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 1999; 37: 423–428.Google Scholar
Prendergast B, Newby DE, Wilson LE, Webb DJ, Mankad PS. Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart 1999; 82: 505–508.Google Scholar
Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease. Vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544–548.Google Scholar
Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236–250.Google Scholar
Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345: 319–324.Google Scholar
De Caestecker M, Meyrick B. Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension. Respir Res 2001; 2: 193–197.Google Scholar
Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741–745.Google Scholar
Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nat Genet 1997; 15: 277–280.Google Scholar
Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research “work in progress”. Circulation 2000; 102: 2781–2791.Google Scholar
Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998; 114: 208S–212S.Google Scholar
Michelakis ED, Dyck JR, McMurtry MS, et al. Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Increasing expression and activity of potassium channels in rat and human models. Adv Exp Med Biol 2001; 502: 401–418.Google Scholar
Gibbs JSR. Recommendations on the management of pulmonary hypertension in clinical practice. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology. Heart 2001; 86 (Suppl 1): i1–i13.Google Scholar
Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385–390.Google Scholar
Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga AC. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest 2001; 120: 894–899.Google Scholar
Roberts DH, Lepore JL, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120: 1547–1555.Google Scholar
Olschweski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329.Google Scholar
Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188–1192.Google Scholar
Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001; 86: 661–665.Google Scholar
Galiè N, Humbert M, Vachiéry J-L, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496–1502.Google Scholar
Ichida F, Uese K-I, Hamamichi Y, et al. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension. Acta Paediatr Jpn 1998; 40: 14–19.Google Scholar
Tulloh RM, Ulmer HE, Gorenflo M. Palliative Therapie von Kindern mit primärer pulmonaler Hypertension mit inhalativen und oralen Prostanoiden. Z Kardiol 2001; 90: 699 (Abstract).Google Scholar
Channick RN, Simoneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.Google Scholar
SoRelle R. Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9–10, 2001. Circulation 2001; 104: E9017–E9018.Google Scholar
International Society for Heart & Lung Transplantation: Annual Registry Data Report available at http://www.ishlt.org.
Bando K, Keenan RJ, Paradis IL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994; 58: 1336–1342.Google Scholar
De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001; 20: 518–524.Google Scholar
Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001; 72: 1673–1679.Google Scholar
Champion HC, Bivalacqua TJ, D'Souza FM, et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res 1999; 84: 1422–1432.Google Scholar
Nabel EG. New approaches to pulmonary hypertension: will therapies in mice work in humans? Circulation 2000; 101: 839–840.Google Scholar
Geraci MW, Gao B, Hoshikawa Y, Yeager ME, Tuder RM, Voelkel NF. Genomic approaches to research in pulmonary hypertension. Respir Res 2001; 2: 210–215.Google Scholar